U.N. negotiations on biodiversty (underway in Nagoya, Japan) have been slowed by disagreement over a protocol that would give developing nations a greater share of profits made by companies that make use of genetic resources found within their borders.
Pharmaceutical and chemical companies regularly explore wild areas of developing nations, searching for unknown organisms that can lead to breakthroughs in medicine and science.
These breakthroughs are part of the justification for preserving large tracks of undeveloped forest regions in poor nations.
Developing nations have refused to agree to new 2020 conservation targets for biodiversity, until a new "access and benefit-sharing" (ABS) protocol is completed.
Negotiators missed a Friday deadline to agree to the new protocol, but it could come by the end of this week, according to a Reuters story.
Read full coverage at the link below.
Loading...